Yaghy Antonio

Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results.

Preliminary efficacy was observed at the maximum tolerated dose. Further studies are warranted to assess long-term safety and efficacy of AGTC-501 for XLRP treatment.

Transscleral Cyclophotocoagulation for Glaucoma in the Setting of Uveal Melanoma.

Painful Glaucoma and Pseudohypopyon in a Child with Retinoblastoma.